Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Renal Function in CABG
NCT06378827Phase 3Recruiting
- Sponsor
- University of Novi Sad
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in acute kidney injury (AKI) (2 arms), sponsored by University of Novi Sad. Primary endpoints: Indicators of renal function (Serum creatinine, Cystatin C, Diuresis, eGFR, CCr) at 5 days, Early biomarker of kidney injury at 2 days and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06378827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378827.